![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1422, 2004-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
HAART introduction in Italy provides cost, QOL advantage
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 445, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
QOL advantage with sildenafil for erectile dysfunction
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 347, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Intermittent HAART no better than continuous for QOL
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 503, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
QOL in HIV infections enhanced with 12 months of HAART
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 400, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
HAART provides protective effects against anaemia
Inpharma, Vol. 1, Iss. 1464, 2004-01 ,pp. :